ÂÜÀòÂÒÂ×

Robert Paul has a diverse work experience spanning various industries. Robert is currently serving as the Chief Executive Officer at Nine Square Therapeutics since January 2022. Prior to this, they worked at Alector as the Chief Medical Officer from October 2016 to January 2022.

Before joining Alector, Robert held multiple roles at Genentech. Robert served as the TA Head Neuro Early Clinical Development gRED from October 2015 to October 2016. Prior to that, they were a Senior Medical Director from October 2013 to September 2015, a Medical Director from September 2011 to October 2013, and an Associate Medical Director from January 2009 to September 2011.

Robert's work experience also includes being a Neurologist at the University of Munich from May 2002 to December 2008. Additionally, they were a Project Leader at Novumed LLC from 2003 to 2008 and an Associate at The Boston Consulting Group from February 2001 to April 2002. Robert began their professional journey as a Research Associate at The Scripps Research Institute from January 1999 to December 2000.

Robert Paul received their Doctor of Medicine (MD) degree from Ludwig-Maximilians-Universität München in 1995. Robert then pursued a PhD from the same university, completing their studies in 1997. In 2006, they enrolled at Universität für Weiterbildung Krems and obtained an MBA in Biotech/Pharma Management in 2010. Additionally, they achieved a Habilitation degree in Neurology from Ludwig-Maximilians-Universität München in 2008. Prior to their higher education, Robert Paul attended Karlsgymnasium, although no specific degree or field of study is mentioned.